Increasing the number of targeted therapies and reducing the cost of genetic testing globally

Company logo

Firm emblem

World lung most cancers genome testing market

Global lung cancer genome testing market

World lung most cancers genome testing market

Dublin, June 22, 2022 (GLOBE NEWSWIRE) – The “Lung Most cancers Genome Testing Market – World and Regional Evaluation: Product Focus, Know-how, Panel Kind, Pattern Kind and Finish Consumer – Evaluation and Forecasting, 2021-2031” Report added to ResearchAndMarkets.com Present.

The marketplace for genomic testing medicine for lung most cancers was valued at $1,262.0 million in 2020 and is predicted to achieve $3,279.8 million by 2031, at a compound annual development charge of 8.97% over the forecast interval 2021-2031.

The expansion within the international lung most cancers genetic testing market is predicted to be pushed by the elevated consciousness and adoption of the lung most cancers genetic testing market, the latest launch of a brand new lung most cancers genetic check, and the growth of analysis into lung most cancers with a spotlight. On pharmacogenomics and growth of concomitant diagnoses.

North America is predicted to dominate the worldwide marketplace for genetic testing for lung most cancers, with the best income of $713.5 million. That is because of the presence of numerous analysis organizations and product and repair corporations in america

Market life cycle stage

The worldwide lung most cancers genetic testing market remains to be within the strategy of being shaped. A number of corporations are rising investments in analysis and growth to facilitate the event of genetic checks for lung most cancers, which is predicted to extend the adoption of genetic testing for lung most cancers.

The shift in well being care techniques towards correct prognosis and precision drugs will result in the adoption of genetic testing for lung most cancers, facilitating knowledgeable therapy selections and bettering well being care outcomes. The rising suggestions by worldwide oncology societies for the usage of genetic testing to diagnose lung most cancers presents vital alternatives within the international lung most cancers genetic testing market.

The presence of main suppliers of in vitro diagnostics (IVD) merchandise for lung most cancers genetic testing in areas reminiscent of North America and Europe has a big influence in the marketplace. For instance, Qiagen gives Therascreen Assays for Strong Tumor, a real-time polymerase chain response (PCR) check for detecting EGFR in non-small cell lung most cancers (NSCLC) sufferers. As well as, Roche gives the Cobas EGFR mutation check, a PCR-based check, and FoundationOne CDx from Basis Drugs Inc. , a subsequent technology sequencing (NGS)-based assay for NSCLC.

LDTs suppliers present genomic lung most cancers checks in areas reminiscent of North America and Europe, which have a big influence in the marketplace. LDT checks are provided by the US Quest Diagnostics and Laboratory Company (Labcorp), which goal completely different lung most cancers genes, for instance, EGFR, MET, ALK and ROS, primarily based on fluorescent in situ hybridization (FISH) and NGS. The presence of those corporations has a optimistic influence on market development.

Impression of COVID-19

Utility in diagnostic laboratories, hospitals and clinics dominates the worldwide lung most cancers genetic testing market. Through the onset of the COVID-19 pandemic, many nations skilled full or partial lockdown, and all elective surgical procedures and procedures in healthcare settings have ceased.

As lung most cancers genomic testing has been categorised beneath the elective process, the influence of the COVID-19 pandemic on lung most cancers genetic testing has been damaging. BIS Analysis evaluation concluded that the market witnessed a 3.24% lower within the annual development charge of the worldwide Lung Most cancers Genetic Testing Market.

Market segmentation

Product sort (merchandise, providers)

The worldwide lung most cancers genetic testing providers sector is predicted to dominate. That is because of the ease of availability, accessibility and flexibility of lab-developed checks, because of the decrease value when in comparison with the IVD product market.

Know-how (polymerase chain response (PCR), subsequent technology sequencing (NGS), fluorescence in situ hybridization, others)

The worldwide marketplace for genomic testing for lung most cancers by polymerase chain response (PCR) is predicted to dominate the worldwide market. That is because of the general cost-efficiency and excessive sensitivity of the PCR-based genetic check for detecting disease-causing mutations in lung most cancers.

Specimen sort (tissue biopsy, liquid biopsy)

The worldwide lung most cancers genomic testing market is predicted to be dominated by tissue biopsy pattern sort. This is because of customary healthcare practices of biopsy extraction of lung tissue to diagnose lung most cancers, which can also be utilized in genetic testing for lung most cancers.

Plaque sort (polygenic plaque, monogenetic plaque)

The worldwide lung most cancers genomic testing market is predicted to be dominated by polygenic panel sort. This is because of customary healthcare practices and healthcare professionals’ familiarity with lung tissue biopsy extraction for lung most cancers prognosis, which can also be utilized in genetic testing for lung most cancers.

Finish Consumer (Analysis Establishment, Hospitals/Clinics, Diagnostic Laboratories, Different Finish Customers)

The top person of the analysis group is predicted to dominate the worldwide lung most cancers genetic testing market. That is because of the massive variety of medical analysis and tutorial establishments the place lung most cancers genetic testing is used to develop medicine, develop concomitant diagnoses, and enroll sufferers in medical trials.

Current Developments within the World Lung Most cancers Genome Testing Market

  • In December 2021, the FDA accredited a companion NGS-based diagnostic from Thermo Fisher Scientific for EGFR Exon20 mutant non-small cell lung most cancers tumor tissue for insertion, the Oncomine Dx Goal Check, now accredited for 12 focused therapies from NSCLC Worldwide.

  • In September 2021, the FDA accredited a tissue-based NGS companion prognosis from Thermo Fisher Scientific for Takeda-targeted remedy for NSCLC sufferers with EGFR Exon20 insertion mutations—the Oncomine Dx Goal Check is now accredited as a CDx for 5 focused therapies for NSCLC in america

  • In September 2020, Laboratory Company of America Holdings entered right into a enterprise partnership with Decision Bioscience; The corporate has carried out a CtDx liquid lung biopsy check.

  • In Could 2021, Qiagen launched the primary FDA-approved histopathological prognosis to establish the KRAS G12C mutation in NSCLC tumors and broaden precision drugs choices in lung most cancers.

  • In January 2020, Qiagen constructed a worldwide collaboration with Amgen to develop an related prognosis of non-small cell lung most cancers.

The most important gamers available in the market and competitors abstract

  • QIAGEN NV

  • Agilent Applied sciences, Inc.

  • Thermo Fisher Scientific, Inc.

  • Quest Diagnostics Included

  • American Laboratories Holding Firm

  • Centogen Nevada

  • BGI

  • CeGaT GmbH

  • Illumina, Inc.

  • F. Hoffmann-La Roche Ltd.

  • Abbott Laboratories

  • Genomics CD

  • NeoGenomics Laboratories

  • Admira Well being

  • Unko DNA

  • OPKO Well being, Inc.

  • Invitae Firm

  • Veracyte, Inc.

Most important subjects coated:

1 markets

2 Market Overview
2.1 Introduction
2.2 World prevalence of lung most cancers
2.3 Significance of genomic testing in lung most cancers
2.4 Impression of COVID-19 on the Lung Most cancers Genome Testing Market
2.4.1 Disruption within the World Lung Most cancers Genome Testing Market: Earlier than and After COVID-19 Market Evaluation
2.4.2 COVID-19 impacts the worldwide lung most cancers genetic testing market provide chain
2.4.3 Medical R&D and industrial operations halted
2.4.4 Navigating restoration from crises and seeking to the long run

3 Business Evaluation
3.1 World Authorized Necessities and Laws
3.1.1 US Authorized Necessities and Frameworks
3.1.1.1 Group of medical care and medical providers facilities
3.1.2 Authorized frameworks and necessities in Europe
3.1.3 Authorized Necessities and Frameworks within the Asia Pacific Area
3.1.4 Latin America (Brazil and Mexico)
3.2 patent scene
3.2.1 Patent submitting development
3.2.2 Patent evaluation by nation
3.2.3 Evaluation of patents by expertise

4 market dynamics
4.1 Overview
4.2 Impression Evaluation
4.3 Market Drivers
4.3.1 Excessive lung most cancers mortality
4.3.2 Advances in Subsequent-Era Applied sciences for Genome Testing
4.3.3 Enhance the variety of focused therapies
4.3.4 Low value of genetic testing globally
4.4 Market Limiting Elements
4.4.1 Unsure regulatory state of affairs for genomic testing
4.4.2 Lack of legitimate tissue biopsy pattern
4.4.3 Unequal reimbursement state of affairs for genomic testing
4.5 Market Alternatives
4.5.1 Bettering international suggestions for genomic testing for lung most cancers
4.5.1.1 Suggestions of the American Society of Medical Oncology (ASCO)
4.5.1.2 Suggestions of the European Society of Medical Oncology (ESMO)
4.5.1.3 Pan-Asian Medical Sensible Tips
4.5.2 Enhance funding in analysis and growth
4.5.3 Rising economies

5 aggressive panorama
5.1 Key Methods and Developments
5.1.1 Synergistic actions
5.1.2 Regulatory approvals
5.1.3 Product launches and promotions
5.1.4 Mergers and Acquisitions
5.1.5 Enterprise Growth
5.1.6 Funding, Financing and Joint Ventures
5.1.7 Market share evaluation by the corporate
5.1.8 Development and inventory evaluation by firm

6 World Lung Most cancers Genome Testing Market, (by Product Kind), Million {Dollars}, 2020-2031
6.1 Overview
6.1.1 Merchandise
6.1.2 Providers

7 World Lung Most cancers Genetic Testing Market, (by expertise), Million {Dollars}, 2020-2031
7.1 Overview
7.2 Subsequent technology sequencing
7.3 Polymerase chain response (PCR)
7.4 In situ hybridization (FISH) / In situ hybridization (ISH)
7.5 different

8 World Lung Most cancers Genome Testing Market, (by Panel Kind), Million {Dollars}, 2020-2031
8.1 Overview
8.2 One gene
8.3 polygenic panel

9 World Lung Most cancers Genetic Testing Market, (by pattern sort), Million {Dollars}, 2020-2031
9.1 Overview
9.2 Tissue biopsy
9.3 Liquid biopsy
9.3.1 CFDNA
9.3.2 ctDNA

10 World Lung Most cancers Genetic Testing Market, (by finish person), Million {Dollars}, 2020-2031
10.1 Overview
10.2 Analysis Group
10.3 Hospitals / Clinics
10.4 Diagnostic laboratories
10.5 Different customers

11 World Lung Most cancers Genetic Testing Market (by Area), Million {Dollars}, 2020-2031
11.1 Overview

12 Firm Profiles
12.1 Firm Overview
12.2 Function within the World Lung Most cancers Genome Testing Market
12.3 Most important rivals
12.4 Most important prospects
12.5 Finance
12.6 Firm Methods
12.7 SWOT Evaluation

For extra info on this report go to https://www.researchandmarkets.com/r/ngy4vz

Connected

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wooden, Senior Press Supervisor press@researchandmarkets.com For E.S.T Workplace Hours Name 1-917-300-0470 For U.S./CAN Toll Free Name 1-800-526-8630 For GMT Workplace Hours Name +353-1-416-8900